For decades, therapeutic monoclonal antibody (mAb) production relied on traditional batch-based manufacturing using stainless steel systems. But as biopharmaceutical pipelines grow to meet rising ...
“By 2016, six out of ten of the blockbusters will be monoclonal-antibody-based therapeutics. With patent protection ending on many of these blockbusters by 2020 and this market estimated to be worth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results